



**INVEST LIKE A PRO, WITH THE PROS!**





Ken d'Entremont, CEO, Medexus Pharmaceuticals

**Medexus Pharmaceuticals**  
**(TSXV:MDP)** is developing into a...

...**"preeminent specialty pharmaceutical company"**, according to new analyst research, which gives the stock at least **65% upside**.

One of the main products for Medexus grew revenue at a **triple digit pace** in the latest quarter.

The company is **EBITDA positive**, and getting

ready to deploy its \$27 million in cash for a transformational acquisition.

[Watch our video interview](#) with the CEO of this unheralded company, *Ken d'Entremont*, to find out what you may be missing.

Sponsor content.

---

And don't forget to access the new [Capital Ideas Digest](#) for "The Best Retail Stock to Buy Today."

This company is hitting all the right notes with the consumers that matter.

---

[www.capitalideasmedia.com](http://www.capitalideasmedia.com)

---

## **Morning Need to Know**

Getting you ready for your investing day

**October 23, 2019**

Written & compiled by Mark Bunting, Publisher,  
Capital Ideas Media

---



---

## **CANADIAN ANALYSTS' CALLS**

**Minto Apartment REIT (TSX:MI.UN)**. CIBC Capital Markets raises the price target to \$24.50 (Canadian) from \$23 and reiterates "outperformer" rating.

**Aecon Group (TSX:ARE)**. Saying that the design engineering and construction company's "already compelling growth outlook has improved over the last five months", Canaccord Genuity maintains an "outperform" rating and a target of \$27.

Analyst Yuri Lynk went on to say:

*"Aecon is a company firmly in growth mode with trailing twelve months free cash flow per share increasing by 29% year-over-year in Q2/2019.*

*This reflects Aecon's strong competitive position in the robust Canadian infrastructure market that has allowed it to build a near-record backlog providing visibility into the mid-2020s.*

*Aecon has \$188 million of net cash on the balance sheet, hidden value potential in its diverse portfolio of concession assets, and a 3.2% dividend yield."*

**Canadian National Railway (TSX:CNR)**. RBC lowers the target to \$127 from \$137 after an unexpected reduction in the company's earnings guidance.

---

# U.S. ANALYSTS' CALLS

---

**Biogen (NASDAQ:BBIB)**. RBC hikes the target to \$267 (U.S.) from \$236 after the company indicated it would seek FDA approval for its promising Alzheimer's treatment.

---

## STOCKS THAT MAY MOVE

---

**Canadian National Railway (TSX:CNR)** cut its adjusted profit forecast and said the first half of 2020 will be challenging.

**Rogers Communications (TSX:RCI.B)** cut its revenue projection due to fewer subscriber additions.

**CRH Medical (TSX:CRH)** has arranged a new, three-year revolving credit facility that provides up to \$200 million (Canadian) in borrowing capacity, double the previous \$100 million facility.

**Caterpillar (NYSE:CAT)** is down in premarket trading after profit fell from last year on weaker demand and the heavy machinery company cut its 2019 earnings outlook.

**Nike (NYSE:NKE)** said long-time CEO Mark Parker will step down next year and be replaced by board member and former eBay CEO John Donahoe.

---

## MARKETS



S&P/TSX and U.S. equity indices are mixed to lower.

---

## CURRENCIES

---

The Canadian dollar is flat at \$0.7634 (U.S.).

---

## COMMODITIES

---

West Texas Intermediate is down 1.5% to \$53.68 a barrel after U.S. weekly inventories rose more than expected.

Gold is up 0.6% at \$1,496.70 an ounce.

---

Please email questions, comments or concerns to: [customercare@capitalideasresearch.com](mailto:customercare@capitalideasresearch.com)

---

Access, insight and ideas.

**Mark Bunting**  
Publisher,  
**Capital Ideas Media**

[www.capitalideasmedia.com](http://www.capitalideasmedia.com)





---

The information and recommendations made available here (“Information”) by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don’t consider buying or selling any stock without conducting your own due diligence.

You are receiving this email because you are part of our investment network.

[Add us to your address book](#)

[update subscription preferences](#)

---

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5J 3P4 · Canada